The LYPLA1 (Lysophospholipase 1) antibody targets a key enzyme involved in lipid metabolism and signaling. LYPLA1. also known as acyl protein thioesterase 1 (APT1), is a serine hydrolase that catalyzes the hydrolysis of fatty acyl groups from modified proteins, regulating their membrane localization and function. It plays a critical role in depalmitoylating signaling proteins such as Gα subunits, Ras family GTPases, and Src kinases, thereby influencing cellular processes like trafficking, differentiation, and apoptosis. Additionally, LYPLA1 is implicated in metabolic pathways, including the degradation of endocannabinoids like anandamide, linking it to neurological and inflammatory responses.
Dysregulation of LYPLA1 has been associated with metabolic disorders, cancer, and neurodegenerative diseases. For instance, elevated LYPLA1 expression correlates with tumor progression in certain cancers, while its inhibition is explored for therapeutic potential in obesity and insulin resistance. Antibodies against LYPLA1 are essential tools for detecting its expression and activity in tissues or cell lines, enabling studies on post-translational protein modifications and lipid-mediated signaling. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to elucidate LYPLA1's role in health and disease. Both monoclonal and polyclonal variants are available, often validated for specificity across human, mouse, and rat models.